Targeting the nuclear factor kappa B (NFκB) pathway is proposed as therapy for chronic lymphocytic leukemia (CLL). We hypothesized that an omega-3 fatty acids (n-3) supplement would suppress NFκB activation in lymphocytes of Rai Stage 0-1 CLL patients. The initial dose of 2.4 g n-3/day was gradually increased to 7.2 g n-3/day.

After n-3 consumption:
1) plasma n-3 increased;
2) NFκB activation was suppressed in lymphocytes;
3) in vitro sensitivity of lymphocytes to doxorubicin was increased; and
4) expression of 32 genes in lymphocytes was significantly decreased.